Anuh Pharma Limited · NSE:ANUHPHR
Anuh Pharma — H1 FY27 Earnings Presentation
33 slides from Anuh Pharma's earnings presentation, November 2026
Slide 1: Anuh Pharma Ltd. Investor Presentation H1 FY27
ANUH PHARMA LTD. Investor Presentation H1 FY27 | November 2026 BSE - 506260, NSE- ANUHPHR Bloomberg: ANUH IN | Reuters: ANUH.BO www.anuhpharma.com 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement ▪ This presentation may include certain "forward looking statements", based on current expectations, within the meaning of applicable laws and regulations. ▪ Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaim
Slide 3: Table of Contents
01 H1 FY27 & H1 FY 26 Performance 02 Company Overview Table of Contents 03 Infrastructure 04 Future Outlook 05 Corporate Social Responsibility 3
Slide 4: H1 FY27 & H1 FY26 Performance
01 H1 FY27 & H1 FY26 Performance 4
Slide 5: H1 FY27 & H1 FY26 at a Glance
H1 FY27 & H1 FY 26 at a Glance Rs. in Crores Operating Revenue Operating Profit EBITDA Profit Before Tax 379.05 78.11 36.92 31.98 +1.80% YoY +26.23% YoY +39.11% YoY +53.19% YoY Rs. 372.36 Cr in H1 FY26 20.61% margin vs 16.62% LY 9.74% margin vs 7.13% LY 8.44% margin vs 5.60% LY PAT ROCE EPS (Rs.) Pr
Slide 6: Message from the Joint Managing Directors – H1 FY27
Message from the Joint Managing Directors – H1 FY27 H1 FY27 – PROFITABILITY Dear Shareholders, Investors and Partners, In H1 FY27 we chose margin over volume. Revenue Revenue (Cr) 379.05 +1.80% was broadly flat at Rs. 379 Cr, while PAT rose 42% and EBITDA margin improved by 261 bps to 9.7%. EBITDA (
Slide 7: H1 FY27 Financial Performance
H1 FY27 Financial Performance Rs. in Crores Financial Highlights Q2 FY27 Q1 FY27 % QoQ H1 FY27 H1 FY26 % YoY Operating Revenue 185.24 193.81 (4.42) 379.05 372.36 1.80 Operating Profit * 39.96 38.15 4.75 78.11 61.87 26.23 % of Margin 21.57 19.68 20.61 16.62 Other Income 0.61 3.08 (80.23) 3.69 4.37 (1
Slide 8: Five-Year Financial Track Record
Five-Year Financial Track Record Rs. in Crores | FY22 - FY26 Total Revenue EBITDA 87.2 776.0 659.0 671.0 70.4 66.1 537.0 52.0 57.4 491.8 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Profit Before Tax and Profit After Tax PBT PAT 78.3 60.1 61.0 54.2 39.1 47.5 47.4 47.4 30.6 36.2 FY22 FY23 FY24 F
Slide 9: Balance Sheet Strength & Shareholder Returns
Balance Sheet Strength & Shareholder Returns FY22 - FY26 Dividend Outflow (Rs. Cr.) Current Ratio (x) 2.20 2.22 15.03 15.03 12.53 2.11 8.77 10.02 1.98 1.91 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Debt to Equity (x) Cash Conversion Cycle (Days) 0.03 86 72 58 56 61 0.01 0.01 0.00 0.00 FY22 F
Slide 10: Revenue Mix & Customer Concentration
Revenue Mix & Customer Concentration H1 FY27 vs H1 FY26 Domestic vs Export Revenue (Rs. Cr.) Top 5 Customers - Share of Sales Domestic Export H1 FY27 H1 FY26 378 371 135 46% 174 36% 33% 32% 31% 27% 243 196 H1 FY27 H1 FY26 Export Domestic Total 10
Slide 11: Export Revenue by Geography
Export Revenue by Geography % of export sales H1 FY27 H1 FY26 2.5% 3.5% 24.4% 30.3% 32.7% 41.9% 4.1% 3.7% 27.1% 29.7% Asia Europe North America Asia Europe North America Africa Latin America Africa Latin America 11
Slide 12: Product Mix - H1 FY27 vs H1 FY26
Product Mix - H1 FY27 vs H1 FY26 Rs. in Crores Revenue by Product Group H1 FY27 H1 FY26 Erythromycin 107.0 119.3 Sulphadoxine 77.7 33.1 Higher Macrolides 64.7 50.4 Cortico Steroids 41.5 43.4 Gliclazide 24.1 9.7 Pyrazinamide 17.9 20.4 Ambroxol HCL 12.8 13.6 Chloramphenicol 10.9 20.1 Other Items 21.1
Slide 13: Company Overview
02 Company Overview 13
Slide 14: Anuh Pharma at a Glance
Anuh Pharma at a Glance API manufacturer since 1989 ~46% 360 72+ 3 of FY26 revenue from marketing partners / countries served facilities - 2 at Tarapur, 1 at exports customers Mahape Business Profile Infrastructure & Group ▪ One of the largest manufacturers of Macrolides and ▪ Two manufacturing faci
Slide 15: Journey So Far
Journey So Far 1989 - 2026 FOUNDATION 1989 - 2010 GLOBAL APPROVALS 2012 - 2019 SCALE & GROWTH 2020 - 2026 1989 Started manufacturing 2012 Acquired R&D assets of Invent 2020 WHO Geneva pre-qualification Erythromycin salts with capacity of 150 Pharma (Spain); DSIR approval. for Pyrimethamine API. MTPA
Slide 16: Competitive Advantage
Competitive Advantage Market Leadership Why Customers Choose Anuh Products where Anuh holds a leading position Regulatory approvals Erythromycin salts USFDA, EU GMP, WHO-GMP, EDQM CEPs and WHO Geneva pre- qualifications across the portfolio. Environmental, health and safety compliance Pyrazinamide A
Slide 17: Product Portfolio
Product Portfolio 12 therapeutic categories MACROLIDES Erythromycin 11,12 Carbonate · Erythromycin Base · Erythromycin Estolate · Erythromycin Propionate · Erythromycin Ethyl Succinate · Erythromycin Phosphate · Erythromycin Stearate CORTICOSTEROIDS Beclomethasone Dipropionate · Betamethasone Acetat
Slide 18: Board & Senior Management
Board & Senior Management Board of Directors Senior Management Mr. Arun Todarwal / Chairman Mr. Raju Kotadia / CMO - EM Fellow member of the ICAI, in practice since 1981. Has been a BSc Chemistry; part of Anuh Pharma since inception, handling overall sales management. director of several large liste
Slide 19: Shareholding Pattern
Shareholding Pattern As on 30th October 2026 Ownership Structure Promoter & Promoter Group 71.80% Public 28.20% 28.20% Market Capitalisation 71.80% INR 877 Cr. Free Float Market Cap. Promoter & Promoter Group Public INR 247 Cr. 19
Slide 20: Infrastructure
cy) hn =) ~~ UW =) hn J 7) © hon a =
Slide 21: State of the Art Manufacturing Facility
State of the Art Manufacturing Facility Tarapur, Maharashtra 20,920 11 3 2,975 sq. meters site area API blocks intermediate blocks MTPA total capacity USD FDA / EU GMP / WHO Pre-qualified Site Other Facilities Anuh Pharma has an US FDA, EU GMP, WHO pre- ▪ Zero Liquid Discharge effluent control syste
Slide 22: New Site: Tarapur Unit F-10
New Site: Tarapur Unit F-10 MIDC Tarapur, Boisar New site details Inaugurated on 20 October 2026, Tarapur Unit F-10 sits in the same MIDC Tarapur industrial area at Boisar as Tarapur Unit E-17 & E-18. A modern, multi-storey cGMP facility designed for multi-purpose API manufacturing, it adds dedicate
Slide 23: Inside the Tarapur Facility
Inside the Tarapur Facility 23
Slide 24: Manufacturing Facility
Manufacturing Facility
Slide 25: Inside the Plant
Inside the Plant EU GMP / WHO pre-qualified operations Clean-room corridors, reactor halls and finished-goods warehousing at Tarapur.
Slide 26: F-10/1 New Plant
F-10/1 New Plant Plot F-10/1, MIDC Tarapur Main gate Plant building Main gate and plant building at the new F-10/1 site.
Slide 27: F-10/1 New Plant
F-10/1 New Plant Utilities and quality control Boiler house QC laboratory Boiler house and QC laboratory at the new F-10/1 site.
Slide 28: Dedicated Research & Development Facility
Dedicated Research & Development Facility Mahape, Navi Mumbai 10,000 DSIR 2012 sq. ft. R&D facility at Mahape approved R&D centre acquired R&D assets of Invent Pharma, Spain ANALYTICAL DEVELOPMENT CHEMICAL SYNTHESIS PILOT PLANT Facilitate activities that lead to Develop processes and products. Lab s
Slide 29: Future Outlook
04 Future Outlook 29
Slide 30: Future Outlook - Growth Strategy
Future Outlook - Growth Strategy Growth Levers Products Under Development ▪ Extensive volume expansions across our API lines, coupled with high- value regulated market growth. 01 Bisoprolol Fumarate ▪ Continued priority on process innovation and cost optimisation. Beta Blocker/Anti Hypertension ▪ St
Slide 31: Corporate Social Responsibility
05 Corporate Social Responsibility 31
Slide 32: Corporate Social Responsibility
Corporate Social Responsibility Servicing society for a better tomorrow Chhatrapati Shikshan Mandal Indian Development Foundation Churchgate Lions Service Funds Building of a toilet block for about Project Aashayein - education for Promoting sports for specially 3,200 students of the school. underpr
Slide 33: Thank You
Thank You For specific queries, please feel free to contact: Anuh Pharma Ltd. Mr. Darshan Rampariya www.anuhpharma.com BSE: 506260, NSE: ANUHPHR Chief Financial Officer [email protected] 33